## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation. Analyst consensus $186 (+35% upside).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($129.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20260105T210935 | Neutral | Relevance: 100%
- Neurocrine Biosciences, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, where CEO Kyle Gano will discuss the company's advancements. The presentation will be webcast live and a replay will be made available on their investor relations website. Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.

**2. Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure**
- Source: Simply Wall Street | 20260104T210930 | Somewhat-Bearish | Relevance: 100%
- Neurocrine Biosciences (NBIX) shares are under pressure after its Phase 3 KINECT DCP trial for dyskinetic cerebral palsy failed to meet primary and secondary endpoints. Despite recent stock declines, the company remains profitable, and analysts suggest it may be undervalued, trading at a discount to targets. However, its high P/E ratio compared to the biotech sector indicates that investors might be paying a premium for future growth.

**3. Neuroscience drugmaker CEO to speak at J.P. Morgan healthcare event**
- Source: Stock Titan | 20260105T210935 | Neutral | Relevance: 100%
- Neurocrine Biosciences (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, where CEO Kyle Gano will deliver a presentation on the company's neuroscience-focused biopharmaceutical efforts. The presentation will be webcast live from San Francisco and will be available for replay for approximately one month. Neurocrine Biosciences currently has FDA-approved treatments for various neurological and endocrine disorders, along with a robust clinical pipeline.

**4. UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com**
- Source: Investing.com UK | 20260105T153600 | Somewhat-Bearish | Relevance: 100%
- UBS lowered its price target for Neurocrine Biosciences (NASDAQ:NBIX) from $195.00 to $188.00 due to competitive concerns impacting the peak sales estimate for its Crenessity drug. Despite this, UBS maintains a Buy rating, and InvestingPro data indicates strong revenue growth and overall "GREAT" financial health for Neurocrine. The article also mentions varied analyst perspectives on Neurocrine, including H.C. Wainwright and TD Cowen raising price targets, while BMO Capital maintained a "Market Perform" rating.

**5. Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20260104T100930 | Somewhat-Bullish | Relevance: 100%
- Merit Financial Group LLC significantly increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 101.3% in Q3, now holding 14,626 shares valued at $2.05 million. This comes despite recent insider selling, totaling $6.57 million in the last 90 days. Neurocrine Biosciences reported strong Q3 earnings, exceeding expectations with $2.17 EPS and $794.9 million in revenue, contributing to a "Moderate Buy" consensus rating and an average price target of $175.25 from analysts.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Near-term weakness: 6.3% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 15.0x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (4 raises, avg +13%, $186 target (+35%)). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.7B |
| Beta | 0.28 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 15.0 |
| Current P/E | 19.9 |
| YoY Growth | 32.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -5.8% to -7.0% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.0pp (needs >4.0% for momentum thesis). AM_20 at -6.3% indicates price below own 20MA trend. Underperforming sector by 8.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-1.33), momentum weakening. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.04% (CS: 3) | Weak |
| RSI_14 | 35.4 | Neutral |
| MACD Histogram | -1.33 | Bearish |
| vs SMA20 | 0.937x | Below |
| vs SMA50 | 0.937x | Below |
| vs SMA200 | 1.046x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $137.35
- **Stop Loss:** $129.57 (5.7% risk)
- **Target:** $152.91 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 169
- **Position Value:** $23,212.15
- **Portfolio %:** 23.21%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*